

4th July, 2025

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Company Update on Litigation

Dear Sir/Madam,

This is in continuation of our earlier intimations dated 21st November, 2023 and 11th June, 2024, whereby we had informed the Stock Exchanges regarding the filing and admission of the petition filed under Section 9 of the Insolvency and Bankruptcy Code, 2016 (“IBC”) by Piramal Critical Care, Inc., a wholly owned stepdown subsidiary of Piramal Pharma Limited (“PCC Inc.”) against Astral SteriTech Private Limited, a subsidiary of Centrient Pharmaceuticals (“Astral”) before the Hon’ble National Company Law Tribunal, Ahmedabad Bench (“NCLT”).

This is to inform that, pursuant to the implementation of the Resolution Plan approved by the NCLT under Sections 30 and 31 of the IBC, PCC Inc. has received an aggregate sum of USD 2,424,334.15 in settlement of its claim against Astral.

Accordingly, a closure report will be filed by the Insolvency Professional with the Insolvency and Bankruptcy Board of India, thereby marking conclusion of the process under IBC.

Request you to take the above on record.

Thank you,

Yours truly,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com